AR051626A1 - Compuestos de imidazo[1,2-a]piridina,procesos para preparar dichos compuestos,composiciones farmaceuticas que los contienen y usos como moduladores del receptor gaba a - Google Patents

Compuestos de imidazo[1,2-a]piridina,procesos para preparar dichos compuestos,composiciones farmaceuticas que los contienen y usos como moduladores del receptor gaba a

Info

Publication number
AR051626A1
AR051626A1 ARP050104693A ARP050104693A AR051626A1 AR 051626 A1 AR051626 A1 AR 051626A1 AR P050104693 A ARP050104693 A AR P050104693A AR P050104693 A ARP050104693 A AR P050104693A AR 051626 A1 AR051626 A1 AR 051626A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
alkynyl
cycloalkyl
alkenyl
Prior art date
Application number
ARP050104693A
Other languages
English (en)
Inventor
Jose Luis Falco
Benet Albert Palomer
Antonio Guglietta
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of AR051626A1 publication Critical patent/AR051626A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Reivindicacion 1. Un compuesto de imidazo[1,2-a]piridina de formula (1) así como las correspondientes sales farmacéuticamente aceptables; caracterizado porque R1 y R2 se seleccionan independientemente del grupo que consiste en H alquil C1-6 lineal o ramificado, alquenil C2-6, alquinil C2-6, haloalquil C1-6, -O-alquil C1-6, F, Cl, y Br; R3 se selecciona del grupo que consiste en H, alquil C1-6 lineal o ramificado, cicloalquil C3-6, cicloalquil C3-6-alquil C1-6, alquenil C2-6, alquenil C2-6- alquil C1-6, alquinil C2-6, alquinil C2-6-alquil C1-6; R4 se selecciona del grupo que consiste e H, haloalquil C2-6, cicloalquil C3-5, cicloalquil C3-6-alquil C1-6, alquinil C2-6-alquil C1-6, alquil C1-6-O-alquil C1-6, alquil C1-6-NH-alquil C1-6, alquil C1-6-N(dialquil C1-6), -OR5, -NHR5, -NR5R6, como se muestra en el resto de formula (2) fenilalquil C2-6, fenialquenil C2-6, naftil, naftil monosustituido, naftil disustituido, naftilalquil C1-6, naftilalquenil C2-6, furil, furil sustituido, benzofuril, benzofuril sustituido, pirrolil, pirrolil sustituido, isoxazolil, isoxazolil sustituido, benzoisoxazolil, benzoisoxazolil sustituido, imidazolil, imidazolil sustituido, benzoimidazolil, benzoimidazolil sustituido, indolil, indolil sustituido, pirazolil, pirazolil sustituido, tienil, tienil sustituido, benzotienil, benzotienil sustituido, tiazolil, tiazolil sustituido, benzotiazolil, benzotiazolil sustituido, quinolinil, quinolinil sustituido, isoquinolinil, isoquinolinil sustituido, piridil, piridil sustituido, pirazinil, pirazinil sustituido, 6-oxo-1,4,5,6-tetrahidropiridazinil, 6-oxo-1,4,5,6-tetrahidropiridazinil sustituido, tiadiazolil, tiadiazolil sustituido, isotiazolil, isotiazolil sustituido, tienilmetil, 2- oxocromenil, 2-oxocromenol sustituido, 2-(furan-2-il)vinil, oxazolil, oxazolil sustituido, y benzisoxazolil; R5 y R6 se seleccionan independientemente del grupo que consiste en H, alquil C1-6 lineal o ramificado, fenilalquil C1-6, haloalquil C1-6, cicloalquil C3-6, cicloalquil C3-6-alquil C1-6, alquenil C2-6 y alquinil C2-6, alquenil C2-6-alquil C1-6, alquinil C2-6-alquil C1-6, fenil, fenil sustituido, heteroaril, heteroaril sustituido; y R7 y R8 se seleccionan independientemente del grupo que consiste en alquil C2-6 lineal o ramificado, cicloalquil C3-6, alquenil C2-6, alquinil C2-6, -OH, -O-alquil C1-6, -SH, -S-alquil C1-6, halo-alquil C1-6, omega, omega, omega-trifluoroalquil C1-6, -NHalquil C1-6, -Ndialquil C1-6, -NO2, -CN, - SO2alquil C1-6, -COalquil C1-6, -COOalquil C1-6, -CO-NHalquil C1-6, -CONdialquil C1-6, fenil, fenil sustituido, heteroaril y heteroaril sustituido.
ARP050104693A 2004-11-11 2005-11-09 Compuestos de imidazo[1,2-a]piridina,procesos para preparar dichos compuestos,composiciones farmaceuticas que los contienen y usos como moduladores del receptor gaba a AR051626A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04105698 2004-11-11

Publications (1)

Publication Number Publication Date
AR051626A1 true AR051626A1 (es) 2007-01-24

Family

ID=34929843

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104693A AR051626A1 (es) 2004-11-11 2005-11-09 Compuestos de imidazo[1,2-a]piridina,procesos para preparar dichos compuestos,composiciones farmaceuticas que los contienen y usos como moduladores del receptor gaba a

Country Status (24)

Country Link
US (1) US20080200473A1 (es)
EP (1) EP1814880B1 (es)
JP (1) JP2008519805A (es)
KR (1) KR20070084026A (es)
CN (1) CN101065377B (es)
AR (1) AR051626A1 (es)
AT (1) ATE421962T1 (es)
AU (1) AU2005303811A1 (es)
BR (1) BRPI0517796A (es)
CA (1) CA2585315A1 (es)
DE (1) DE602005012598D1 (es)
DK (1) DK1814880T3 (es)
ES (1) ES2321858T3 (es)
IL (1) IL182963A0 (es)
MX (1) MX2007005611A (es)
NO (1) NO20072831L (es)
PA (1) PA8652101A1 (es)
PE (1) PE20060967A1 (es)
PL (1) PL1814880T3 (es)
PT (1) PT1814880E (es)
RU (1) RU2007121864A (es)
TW (1) TWI357412B (es)
UY (1) UY29204A1 (es)
WO (1) WO2006051063A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003220222A1 (en) 2002-03-13 2003-09-29 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2006084033A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
WO2007137954A1 (en) * 2006-05-31 2007-12-06 F. Hoffmann-La Roche Ag Aryl-4-ethynyl-isoxazole derivatives
US20100209345A1 (en) * 2006-08-24 2010-08-19 Australian Nuclear Science & Technology Organisation Fluorinated Ligands for Targeting Peripheral Benzodiazepine Receptors
EP2282735B1 (en) 2008-04-21 2019-01-16 Signum Biosciences, Inc. Pp2a modulators for treating alzheimer, parkinson, diabetes
JP5774982B2 (ja) 2008-05-19 2015-09-09 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． イミダゾ［１，２−ａ］ピリジン化合物
WO2010045615A2 (en) 2008-10-16 2010-04-22 Cenomed Biosciences, Llc Treatment of organophosphate exposure with ocinaplon
US20120010188A1 (en) * 2008-12-04 2012-01-12 Promimagen Ltd. Imidazopyridine Compounds
CN106866667B (zh) 2009-11-05 2019-11-15 圣母大学 咪唑并[1,2-a]吡啶类化合物及其合成及使用方法
TW201225957A (en) * 2010-09-17 2012-07-01 Taisho Pharmaceutical Co Ltd Glycine transporter inhibitor
CA2998375A1 (en) 2015-09-17 2017-03-23 Marvin J. Miller Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
CN106906486B (zh) * 2017-02-22 2018-12-11 华南理工大学 3-溴-2-苯基-咪唑并[1,2-α]吡啶类衍生物的电化学合成方法
WO2021155264A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2568880B1 (fr) * 1984-08-07 1986-12-12 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
FR2593181B1 (fr) * 1986-01-22 1988-04-01 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
FR2593818B1 (fr) * 1986-02-05 1988-04-29 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridine, leur preparation et leur application en therapeutique
EP0234970B1 (fr) * 1986-01-22 1991-04-17 Synthelabo Dérivés d'acylaminométhyl-3 imidazo[1,2-a]pyridines, leur préparation et leur application en thérapeutique
WO2004066930A2 (en) * 2003-01-27 2004-08-12 Arthur Zaks Method for inducing pain relief using imidazo[1,2-a]pyridine derivatives

Also Published As

Publication number Publication date
PE20060967A1 (es) 2006-09-20
KR20070084026A (ko) 2007-08-24
MX2007005611A (es) 2007-07-11
ES2321858T3 (es) 2009-06-12
DK1814880T3 (da) 2009-05-18
BRPI0517796A (pt) 2008-10-28
TW200624432A (en) 2006-07-16
CN101065377B (zh) 2011-07-27
UY29204A1 (es) 2006-01-31
JP2008519805A (ja) 2008-06-12
DE602005012598D1 (de) 2009-03-19
EP1814880A1 (en) 2007-08-08
CN101065377A (zh) 2007-10-31
PL1814880T3 (pl) 2009-07-31
PT1814880E (pt) 2009-04-23
PA8652101A1 (es) 2006-10-13
TWI357412B (en) 2012-02-01
US20080200473A1 (en) 2008-08-21
NO20072831L (no) 2007-08-01
ATE421962T1 (de) 2009-02-15
EP1814880B1 (en) 2009-01-28
AU2005303811A1 (en) 2006-05-18
WO2006051063A1 (en) 2006-05-18
CA2585315A1 (en) 2006-05-18
RU2007121864A (ru) 2008-12-20
IL182963A0 (en) 2007-08-19

Similar Documents

Publication Publication Date Title
AR051626A1 (es) Compuestos de imidazo[1,2-a]piridina,procesos para preparar dichos compuestos,composiciones farmaceuticas que los contienen y usos como moduladores del receptor gaba a
AR114922A1 (es) Moléculas que tienen utilidad plaguicida, y composiciones y procesos, relacionados con ellas
CO2018000344A2 (es) Derivados de piperidina 1,4-sustituidos
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR085354A1 (es) Derivados de isoxazol para control de pestes invertebrados
MA49061A (fr) Dérivés 4-sulfonylaminocarbonylquinoline pour augmenter l'activité cftr
UY30296A1 (es) Compuestos fenil amido heterociclicos condensados
BR112015010102A2 (pt) compostos heterocíclicos substituídos por amida úteis como moduladores de respostas de il-12, il-23 e/ou ifnalfa
MD3317281T2 (ro) Forme solide și formulări de (S)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-α]pirazin-1-il)-N-(piridin-2-il)benzamidă
AR074790A1 (es) Derivados de isooxazol sustituidos, composiciones farmaceuticas y para el control de parasitos que los comprenden y su uso en metodos para controlar parasitos en y sobre animales de sangre caliente.
AR060545A1 (es) Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas
EA201791461A1 (ru) Бензодиазепиновые димеры с мостиковым гетероариленом, их конъюгаты, способы получения и применение
CR20130680A (es) Métodos plaguicidas que utilizan compuestos de 3-piridil tiazol sustituido y derivados para combatir las plagas de animales i
AR059622A1 (es) Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles
AR051780A1 (es) Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
BRPI0616574A2 (pt) derivado de sulfonamida tendo atividade antagonìstica de receptor de pgd2
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR078535A1 (es) Derivados de pirrolo[2,3-b]piridina ligandos de receptores estrogenicos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la osteoporosis y enfermedades del sistema nervioso central, entre otras
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
DOP2012000318A (es) Compuestos heterociclicos fusionados
NZ592238A (en) Pharmaceutical compositions comprising 4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine derivatives
MX2018015302A (es) Esteres de acidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y metodos para usar los mismos.
PE20190339A1 (es) 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal